Brainstorm Diagnostics

Brainstorm Diagnostics is a cutting-edge diagnostic company dedicated to commercializing technology that predicts outcomes after concussion. Focused on addressing the challenges of mild traumatic brain injury (mTBI), Brainstorm Diagnostics aims to provide precision in diagnosing and predicting recovery timelines for individuals who have experienced a concussion. The company is committed to advancing the understanding and treatment of concussions through innovative diagnostic solutions.

Brainstorm Diagnostics leverages a patent-protected technology exclusively licensed from the University of Pennsylvania. This technology centers around detecting individuals who have experienced axonal injury after a concussion, making them more likely to have a delayed recovery. By focusing on blood biomarkers, particularly the molecule known as spectrin N terminal fragment (SNTF), Brainstorm Diagnostics is at the forefront of identifying those who require more intensive and prolonged care.

Founded in 2023, Brainstorm Diagnostics is poised to make a significant impact on the medical and diagnostic landscape. The company's dedication to innovation and precision positions it as a key player in improving patient outcomes and advancing concussion treatment. The management team will soon complete additional company information to enhance our platform. We invite the manager of Brainstorm Diagnostics to create a customized and exclusive company showcase and product listing on our platform.